21 cases from 10 districts over the blood-thinning drug Xarelto were consolidated into a multidistrict litigation (“MDL”) for pretrial proceedings before Judge Fallon in New Orleans. Meanwhile, more Xarelto lawsuits continue to mount, with 86 suits pending, according to the Judicial Panel on Multidistrict Litigation’s January 15, 2015 monthly report. All contend that the anticoagulant manufactured and marketed to safely and effectively clot blood has failed to do so, causing uncontrolled, sometimes fatal, bleeding. Consolidating the initial 21 suits allows the court to more efficiently address the nearly identical claims that Xarelto’s manufacturers, Bayer Healthcare and Janssen Pharmaceuticals, did not properly communicate the risks associated with Xarelto, including the fact that there is no known bleeding antidote for the drug. As the bellwether trials near, more lawsuits are likely to join the 86 suits pending in the MDL.